Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA

Key Takeaways:

• Cassava Sciences faces a class-action securities lawsuit alleging investor deception.
• The company’s Alzheimer’s drug, simufilam, failed to meet all key endpoints in a Phase 3 trial.
• Stock prices fell dramatically by approximately 83.76% following the trial results.
• Investors have until February 10, 2025, to request appointment as lead plaintiff in the lawsuit.
• Law firm Levi & Korsinsky, LLP is leading the legal action on behalf of affected shareholders.

Cassava Sciences Sued After Alzheimer’s Drug Failure

Introduction

Cassava Sciences, Inc., a biotechnology firm specializing in Alzheimer’s treatments, is confronting a class-action securities lawsuit following the failure of its leading drug candidate, simufilam, in a critical Phase 3 trial. The lawsuit, initiated by Levi & Korsinsky, LLP, alleges that the company misled investors about the drug’s potential, resulting in significant financial losses when the trial results were announced.

Simufilam’s Phase 3 Trial Disappointment

On November 25, 2024, Cassava Sciences released topline results from the “ReThink-ALZ” study, the first of its two ongoing Phase 3 trials for simufilam. The data revealed a stark reality: “Simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints.” Essentially, the drug did not demonstrate effectiveness beyond a placebo in treating Alzheimer’s Disease.

Dramatic Stock Price Decline

The market reacted swiftly to the news of simufilam’s failure. Cassava’s stock price plummeted from a closing market price of $26.48 per share on November 22, 2024, to just $4.30 per share on November 25, 2024. This represents a staggering decline of approximately 83.76% in a single day, erasing significant shareholder value.

Allegations of Misleading Investors

According to the complaint filed by Levi & Korsinsky, “defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam,” expressing clear confidence in its ability to treat Alzheimer’s Disease. The lawsuit alleges that these statements were misleading, constituting securities fraud that adversely affected investors once the true efficacy of simufilam was revealed.

Details of the Class-Action Lawsuit

The class-action suit seeks to recover losses on behalf of investors who purchased Cassava Sciences stock between February 7, 2024, and November 24, 2024. Affected investors have until February 10, 2025, to request that the court appoint them as lead plaintiff. Participation in the lawsuit does not require serving as lead plaintiff to share in any potential recovery.

Investor Guidance and Next Steps

Levi & Korsinsky emphasizes that “there is no cost or obligation to participate” for class members. Investors who suffered losses during the specified period are encouraged to contact the law firm to explore their legal options. With a track record of representing investors in complex securities litigation, the firm is poised to lead the legal effort against Cassava Sciences.

Conclusion

The failure of simufilam not only marks a setback in the fight against Alzheimer’s Disease but also serves as a cautionary tale about investor reliance on corporate communications. The pending lawsuit underscores the potential repercussions for companies that allegedly mislead shareholders, highlighting the importance of transparency and accountability in the pharmaceutical industry.